naltrexone and semaglutide Currently Approved Medications For Obesity 1️⃣ Orlistat: 3.1% Weight Loss 2️⃣ Naltrexone-Buproprion: 4.1% Weight Loss 3️⃣ Liraglutide: 4.7% Weight Loss 4️⃣ Phentermine-Topiramate: 8% Weight Loss 5️⃣ Semaglutide: 11-12% Weight Loss 6️⃣ exclude discount Color:Lavender GLP-1 Updates 2024 |

naltrexone and semaglutide Currently Approved Medications For Obesity 1️⃣ Orlistat: 3.1% Weight Loss 2️⃣ Naltrexone-Buproprion: 4.1% Weight Loss 3️⃣ Liraglutide: 4.7% Weight Loss 4️⃣ Phentermine-Topiramate: 8% Weight Loss 5️⃣ Semaglutide: 11-12% Weight Loss 6️⃣ exclude discount Color:Lavender GLP-1 Updates 2024 |

GLP-1 Updates 2024 | Innovative Rx Strategies

There’s a big footnote for this trial that takes us back to the Bhaumik award and why there was such a long time before the realization the GLP-1 drugs could be useful for obesity—people with diabetes on GLP-1 drugs didn’t lose much weight

exclude discount

Color:Lavender

Methodologies, limitations, and citations are also available in the full report